Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen McCarthy

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Blood Advances|April 15, 2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-upRoger G Owen, Helen McCarthy, Shirley D'Sa, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
British Journal of Haematology|July 6, 2016
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A Eyre, Ruth Clifford, Adrian Bloor, et al.
British Journal of Cancer|November 28, 2019
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancerStephanie Annett, Gillian Moore, Amy Short, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
British Journal of Haematology|November 20, 2020
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II studyAjai Chari, Paula Rodriguez-Otero, Helen McCarthy, et al.
Blood Advances|April 15, 2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-upRoger G Owen, Helen McCarthy, Shirley D'Sa, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
British Journal of Haematology|July 6, 2016
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A Eyre, Ruth Clifford, Adrian Bloor, et al.
British Journal of Cancer|November 28, 2019
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancerStephanie Annett, Gillian Moore, Amy Short, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Pageof 7